Loading...
Blood-based RAS mutation testing: concordance with tissue-based RAS testing and mutational changes on progression
Germetaki, Theodora Nicholls, Camille Adams, R. A. Braun, Michael S Rogan, Jane Moghadam, Sharzad Lenfert, E. Lukas, A. Edelstein, D. L. Jones, F. S.
Germetaki, Theodora
Nicholls, Camille
Adams, R. A.
Braun, Michael S
Rogan, Jane
Moghadam, Sharzad
Lenfert, E.
Lukas, A.
Edelstein, D. L.
Jones, F. S.
Citations
Altmetric:
Abstract
Aim: To determine the concordance between plasma and tissue RAS mutation status in metastatic colorectal cancer patients to gauge whether blood-based testing is a viable alternative. We also evaluated the change in mutation status on progression. Materials/methods: RAS testing was performed on plasma from patients commencing first-line therapy (OncoBEAM™ RAS CEIVD kit). Results were then compared with formalin-fixed paraffin embedded tumor samples. Results: The overall percentage agreement (concordance) was 86.0% (86/100), which demonstrates that blood-based testing is an alternative to tissue-based testing. Reproducibility was 100% between three laboratories and 20% showed changes in their RAS mutational status on progression. Conclusion: These results show good concordance between tissue and plasma samples and suggest the need for longitudinal plasma testing during treatment to guide management decisions.
Keywords: BEAMing; RAS; circulating-free DNA; colon cancer; ctDNA; mCRC.
Description
Date
2020
Publisher
Collections
Files
Loading...
From UNPAYWALL
Adobe PDF, 2.7 MB
Keywords
Type
Article
Citation
Germetaki T, Nicholls C, Adams RA, Braun M, Rogan J, Moghadam S, et al. Blood-based RAS mutation testing: concordance with tissue-based RAS testing and mutational changes on progression. Future Oncol. 2020.